Value of miR-1271 and glypican-3 in evaluating the prognosis of patients with hepatocellular carcinoma after transcatheter arterial chemoembolization

Table 4 Comparison of serum glypican-3 and miR-1271 levels in patients with hepatocellular carcinoma

Group	Number of cases	Glypican-3	t	P value	miR-1271	t	P value
Group 1			7.41	< 0.05		18.06	< 0.05
Health group	162	0.74 ± 0.29			5.48 ± 1.79
Cancer group	162	8.87 ± 3.73			1.25 ± 0.68
Group 2			18.06	< 0.05		18.06	< 0.05
Before treatment	162	8.87 ± 3.73			1.25 ± 0.68
After treatment	162	2.46 ± 1.69			4.64 ± 2.13
Group 3			7.6	< 0.05		4.17	< 0.05
Remission group	112	6.79 ± 5.32			4.96 ± 2.28
Recurrent group	50	8.74 ± 2.40			3.41 ± 1.96